Analyst Price Target is $12.40
▲ +293.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is $12.40, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 293.65% upside from the last price of $3.15.
Current Consensus is
Buy
The current consensus among 5 investment analysts is to buy stock in SAB Biotherapeutics. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Read More
